ES2390092T3 - Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas - Google Patents

Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas Download PDF

Info

Publication number
ES2390092T3
ES2390092T3 ES06807100T ES06807100T ES2390092T3 ES 2390092 T3 ES2390092 T3 ES 2390092T3 ES 06807100 T ES06807100 T ES 06807100T ES 06807100 T ES06807100 T ES 06807100T ES 2390092 T3 ES2390092 T3 ES 2390092T3
Authority
ES
Spain
Prior art keywords
formula
compounds
group
complex
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06807100T
Other languages
English (en)
Spanish (es)
Inventor
Marc Port
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet SA filed Critical Guerbet SA
Application granted granted Critical
Publication of ES2390092T3 publication Critical patent/ES2390092T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES06807100T 2005-10-07 2006-10-09 Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas Active ES2390092T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0510289 2005-10-07
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US73475605P 2005-11-09 2005-11-09
US734756P 2005-11-09
PCT/EP2006/067214 WO2007042506A1 (en) 2005-10-07 2006-10-09 Compounds comprising short aminoalcohol chains and metal complexes for medical imaging

Publications (1)

Publication Number Publication Date
ES2390092T3 true ES2390092T3 (es) 2012-11-06

Family

ID=36636179

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06807100T Active ES2390092T3 (es) 2005-10-07 2006-10-09 Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas
ES12153144.6T Active ES2519369T3 (es) 2005-10-07 2006-10-09 Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12153144.6T Active ES2519369T3 (es) 2005-10-07 2006-10-09 Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas

Country Status (16)

Country Link
US (1) US8114863B2 (enExample)
EP (2) EP2457914B1 (enExample)
JP (2) JP5317270B2 (enExample)
KR (2) KR101440761B1 (enExample)
CN (2) CN101305006B (enExample)
BE (1) BE2024C510I2 (enExample)
BR (1) BRPI0617151B8 (enExample)
CA (1) CA2625207C (enExample)
DK (1) DK1931673T3 (enExample)
ES (2) ES2390092T3 (enExample)
FI (1) FIC20240003I1 (enExample)
FR (2) FR2891830B1 (enExample)
NL (1) NL301259I2 (enExample)
PL (1) PL1931673T3 (enExample)
PT (1) PT1931673E (enExample)
WO (1) WO2007042506A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
US20110077396A1 (en) * 2009-09-30 2011-03-31 General Electric Company Intermediates for hydroxylated contrast enhancement agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
DK2766364T3 (da) * 2011-08-17 2024-09-30 Merck & Cie Folatkonjugater af albumin-bindende enheder
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
KR102231121B1 (ko) * 2013-04-26 2021-03-23 게르브 조영제 제형 및 이와 관련된 제조 방법
CN103467504B (zh) * 2013-09-23 2015-06-24 武汉工程大学 18f-氟标记卟啉-异氮杂茚自由基配合物及合成方法
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
PL3753929T3 (pl) * 2015-12-10 2023-03-13 Bracco Imaging Spa Dimeryczne środki kontrastowe
EP3223181B1 (en) 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
JP6909234B2 (ja) * 2016-04-13 2021-07-28 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 造影剤
GB201610738D0 (en) * 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
WO2018115314A1 (en) * 2016-12-21 2018-06-28 Ge Healthcare As Tetraazabicyclo-macrocycle based manganese chelate compounds suitable as mri imaging agents
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN111712477B (zh) 2017-12-20 2024-02-02 通用电气公司 阴离子螯合物化合物
WO2020030618A1 (en) 2018-08-06 2020-02-13 Bracco Imaging Spa Gadolinium bearing pcta-based contrast agents
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
FR3091873B1 (fr) 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
HUE064567T2 (hu) 2020-07-16 2024-03-28 Guerbet Sa Eljárás 2-bróm-glutársav-diészterek elõállítására
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
US20230339945A1 (en) 2020-07-17 2023-10-26 Guerbet Method for preparing a chelating ligand derived from pcta
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
JP7895667B2 (ja) * 2022-09-01 2026-07-28 テラノキュア カンパニー リミテッド 新規化合物、およびこれを含むｍｒｉ造影剤
KR102845061B1 (ko) * 2022-09-01 2025-08-13 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
US20240325574A1 (en) * 2023-04-03 2024-10-03 Molecular Theranostics, Llc Extradomain b fibronectin targeting peptides and derivatives for cancer imaging and therapy
EP4464708A1 (en) 2023-05-17 2024-11-20 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
CN121666388A (zh) 2023-09-01 2026-03-13 江苏恒瑞医药股份有限公司 一种大环化合物及其用途
CN118791488B (zh) * 2024-09-14 2024-11-15 成都施贝康生物医药科技有限公司 化合物、螯合物及其在磁共振成像中的应用
CN118834263B (zh) * 2024-09-14 2024-12-03 成都施贝康生物医药科技有限公司 含短氨基醇链的化合物及其金属络合物和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135748A (en) 1960-05-27 1964-06-02 Little Inc A Heterocyclic substituted carbodhmides and method of preparation
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE4001655A1 (de) * 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE3825040A1 (de) * 1988-07-20 1990-01-25 Schering Ag, 13353 Berlin 5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
HUT67602A (en) 1991-12-10 1995-04-28 Dow Chemical Co Process for producing bicyclo-polyaza-macrocyclo-carboxylic acid complexes, their conjugates and contrast materials containing them
ES2156143T3 (es) * 1993-12-30 2001-06-16 Guerbet Sa Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas.
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6071490A (en) * 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
EP1203026A4 (en) 1999-07-29 2005-03-16 Dyax Corp BINDING CENTERS FOR FIBRIN
AU2001236485A1 (en) * 2000-01-21 2001-07-31 Mallinckrodt, Inc. Novel orthogonally protected amino acid chelators for biomedical applications
US6450956B1 (en) 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
ITMI20011518A1 (it) * 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
CA2526760A1 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US20050136003A1 (en) 2003-10-31 2005-06-23 Casebier David S. Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
US20080124270A1 (en) 2003-12-23 2008-05-29 Bracco Imaging S.P.A. Compounds Useful as Metal Chelators
EP1765812B1 (en) * 2004-07-02 2009-04-29 Bracco Imaging S.p.A Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Also Published As

Publication number Publication date
BE2024C510I2 (enExample) 2026-01-14
FR2891830B1 (fr) 2011-06-24
FR2891830A1 (fr) 2007-04-13
WO2007042506A1 (en) 2007-04-19
PT1931673E (pt) 2012-09-24
CN103224495B (zh) 2015-07-15
CN101305006A (zh) 2008-11-12
CA2625207C (en) 2014-05-13
KR20140060565A (ko) 2014-05-20
FIC20240003I1 (fi) 2024-02-26
EP1931673B1 (en) 2012-08-29
CN101305006B (zh) 2013-04-24
JP5731572B2 (ja) 2015-06-10
EP1931673A1 (en) 2008-06-18
KR101440761B1 (ko) 2014-09-17
JP2009513574A (ja) 2009-04-02
BRPI0617151A2 (pt) 2011-07-12
EP2457914B1 (en) 2014-08-06
DK1931673T3 (da) 2012-10-08
PL1931673T3 (pl) 2012-11-30
FR24C1006I1 (fr) 2024-04-19
JP2013209400A (ja) 2013-10-10
JP5317270B2 (ja) 2013-10-16
US20090169479A1 (en) 2009-07-02
US8114863B2 (en) 2012-02-14
CN103224495A (zh) 2013-07-31
KR20080080495A (ko) 2008-09-04
BRPI0617151B1 (pt) 2020-08-11
CA2625207A1 (en) 2007-04-19
BRPI0617151B8 (pt) 2021-07-27
FR24C1006I2 (fr) 2025-02-07
NL301259I2 (nl) 2024-03-25
ES2519369T3 (es) 2014-11-06
EP2457914A1 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
ES2519369T3 (es) Compuestos que comprenden cadenas de aminoalcohol cortas y complejos metálicos para la obtención de imágenes médicas
JP5368099B2 (ja) ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
ES2756703T3 (es) Nuevos compuestos de quelato de gadolinio para su uso en la obtención de imágenes por resonancia magnética
CN108368067B (zh) 二聚造影剂
JP2003201258A (ja) 多座結合を介した多量体画像化剤の標的化
CA2453214A1 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy
CA2453106A1 (en) Macrocyclic metal complexes and use thereof for production of conjugates with biomolecules
ES2386073T3 (es) Compuestos para el diagnóstico de enfermedades relacionadas con la expresión de VCAM
ES2899033T3 (es) Agentes de contraste diméricos
ES2205863T3 (es) Derivados paramagneticos de deuteroporfirinas sustituidas en las posiciones 3, 8, agentes farmaceuticos que contienen estos derivados, procedimientos para su preparacion y su utilizacion para la representacion en imagenes por mr de las necrosis y los infartos.
JP4878119B2 (ja) エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ニトロベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用
AU2006272025A1 (en) Complexes containing perfluoroalkyl, method for the production and use thereof
JP5162081B2 (ja) エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸と生体分子との結合体、その塩の製造方法並びに医薬品の製造のためのそれらの使用
AU2005202428B2 (en) Targeting Multimeric Imaging Agents Through Multilocus Binding
CN116375709A (zh) 一种叶酸受体靶向药物、金属络合物及其制备方法与用途
HK1257515B (en) Dimeric contrast agents
HK1257515A1 (en) Dimeric contrast agents